Author

Petr Karlov

Observed names: P A Karlov, P. A. Karlov, P. Karlov, P.A. Karlov, Petr A Karlov, Petr Alexandrovich Karlov

Institution: City Clinical Oncology Center

Observed institutions: St Petersburg University, Baylor College of Medicine, Yale University, Virginia Oncology Associates, Russian Cancer Research Center NN Blokhin, Leningrad Regional Cancer Center, City Clinical Oncology Center, Rocky Mountain Cancer Centers, Willamette Valley Cancer Institute and Research Center, Chelyabinsk Regional Clinical Oncology Center

ORCID: 0009-0008-3673-3325

Observed ORCID: 0009-0008-3673-3325

OpenAlex ID: A5034366168

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

2021 · Thomas Powles, Tibor Csőszi, et al. · The Lancet Oncology · 665

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

2017 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet · 175

PDF

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

2011 · G. Sonpavde, V. Matveev, et al. · Annals of Oncology · 149

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

2019 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet Oncology · 93

Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.

2012 · Brian I. Rini, Viktor Grünwald, et al. · Journal of Clinical Oncology · 36

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

2016 · Robert E. Hawkins, Martin Gore, et al. · Clinical Cancer Research · 33

A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.

2013 · Robert E. Hawkins, Martin Eric Gore, et al. · Journal of Clinical Oncology · 5

Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with metastatic or locally advanced unresectable or recurrent urothelial transitional cell cancer (TCC)

2004 · A. Gorelov, S. Gorelov, et al. · Journal of Clinical Oncology · 5

Comparative Survival Evaluation in Patients With Kidney Cancer After Endovideosurgical Radical Nephrectomy and Renal Resection

2014 · S. V. Popov, R. G. Guseinov, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 3

A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)

2011 · G. Sonpavde, V. B. Matveev, et al. · Journal of Clinical Oncology · 3

Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)

2009 · R. L. De Jager, L. Roman, et al. · Journal of Clinical Oncology · 3

Sarcomatoid carcinoma of the bladder: clinical observation and literature review

2024 · D. V. Semyonov, R. V. Orlova, et al. · Cancer Urology · 2

PDF

Efficacy of incomplete metastasectomy in combination with targeted therapy in metastatic kidney cancer patients

2019 · P. S. Borisov, R. V. Orlova, et al. · Cancer Urology · 2

PDF

Efficacy of incomplete metastasectomy with targeted therapy in patients with metastatic renal cell carcinoma.

2016 · Rashida Orlova, Pavel Borisov, et al. · Journal of Clinical Oncology · 2

Surgical treatment in patients with kidney cancer metastasizing to the spine

2014 · S. V. Kostritsky, V. I. Shirokorad, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 2

A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)

2008 · H. B. Breitz, L. A. Roman, et al. · Journal of Clinical Oncology · 2

Features of the clinical course of penile cancer

2024 · T. Kh. Nazarov, P. A. Shcheplev, et al. · Andrology and Genital Surgery · 1

Evaluation of the efficiency of combination palliative treatment in patients with metastatic clear-cell renal cell carcinoma

2015 · P. S. Borisov, R. V. Orlova, et al. · Cancer Urology · 1

PDF

Percutaneous Vertebroplasty in Patients With Kidney Cancer Metastases to the Vertebral Column

2014 · S. V. Kostritsky, D. V. Semenov, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 1

Phase I study of picoplatin and docetaxel (D) with prednisone (P) in patients (pts) with chemotherapy-naive metastatic hormone refractory prostate cancer (HRPC)

2007 · L. Roman, P. Karlov, et al. · Journal of Clinical Oncology · 1

Supplementary Figure 3S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis